Population pharmacokinetic analysis of piperacillin in burn patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3744-3751

  Jeon, Sangil ^a   Han, Seunghoon ^a   Lee, Jongtae ^a   Hong, Taegon ^a   Paek, Jeongki ^a   Woo, Heungjeong ^b   Yim, Dong Seok ^a  

^a The Catholic University of Korea   (South Korea)

^b Hallym University Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGED; ARTICLE; BURN; BURN PATIENT; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICHAELIS MENTEN KINETICS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; SEPSIS; STEADY STATE; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; COMPLICATION; COMPUTER SIMULATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURNS; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; YOUNG ADULT;

EID: 84903180987     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02089-13     Document Type: Article

References (32)

1. Perry C, Markham A. 1999. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805. http://dx.doi.org/10.2165/00003495-199957050-00017.
2. Lederle Laboratories. 1999. Piperacillin sodium and tazobactam sodium (Zosyn) product information. Lederle Laboratories, Pearl River, NY.
3. Rezaei E, Safari H, Naderinasab M, Aliakbarian H. 2011. Common pathogens in burn wound and changes in their drug sensitivity. Burns 37:805-807. http://dx.doi.org/10.1016/j.burns.2011.01.019.
4. Church D, Elsayed S, Reid O, Winston B, Lindsay R. 2006. Burn wound infections. Clin. Microbiol. Rev. 19:403-434. http://dx.doi.org/10.1128/CMR.19. 2.403-434.2006.
5. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10. http://dx.doi.org/10.1086/516284.
6. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10.1038/nrmicro862. (Pubitemid 39490099)
7. Weinbren M. 1999. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. 44:319-327. http://dx.doi.org/10.1093/jac/44.3.319. (Pubitemid 29425682)
8. European Committee on Antimicrobial Susceptibility Testing. 2010. Piperacillin-tazobactam: rationale for the clinical breakpoints, version 1.0. EUCAST Laboratory for Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Rationale- documents/Piperacillin-tazobactam-rationale-Nov2010-v-1.0.pdf.
9. Rhomberg PR, Jones RN. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn. Microbiol. Infect. Dis. 65:414-426. http://dx.doi.org/10.1016/j.diagmicrobio.2009.08.020.
10. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y. 2011. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med. J. 52:793-802. http://dx.doi.org/10.3349/ ymj.2011.52.5.793.
11. Bulitta J, Duffull S, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano G, Sörgel F. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507. http://dx.doi.org/10.1128/AAC.01477-06. (Pubitemid 47047329)
12. Dowell JA, Korth-Bradley J, Milisci M, Tantillo K, Amorusi P, Tse S. 2001. Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment. J. Clin. Pharmacol. 41:979-986. http://dx.doi.org/10.1177/00912700122010960. (Pubitemid 32786572)
13. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. 2010. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int. J. Antimicrob. Agents 35:156-163. http://dx.doi.org/10.1016/j. ijantimicag.2009.10.008.
14. Arzuaga A, Isla A, Gascón A, Maynar J, Martin A, Solinís M, Toral D, Pedraz J. 2005. Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. Biomed. Chromatogr. 19:570-578. http://dx.doi.org/10.1002/bmc.482. (Pubitemid 41448282)
15. Al-Nawas B, Kinzig-Schippers M, Soergel F, Shah PM. 2008. Concentrations of piperacillin-tazobactam in human jaw and hip bone. J. Craniomaxillofac. Surg. 36:468-472. http://dx.doi.org/10.1016/j.jcms.2008.06.003.
16. Cockcroft D, Gault M. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
17. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H. 1996. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob. Agents Chemother. 40:139-145. (Pubitemid 26020754)
18. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. 2005. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J. Antimicrob. Chemother. 56:388-395. http://dx.doi.org/10.1093/jac/dki243. (Pubitemid 41158530)
19. Blanchet B, Jullien V, Vinsonneau C, Tod M. 2008. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin. Pharmacokinet. 47:635-654. http://dx.doi.org/10.2165/00003088- 200847100-00002.
20. Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim D-S. 2010. Population pharmacokinetics of meropenem in burn patients. J. Antimicrob. Chemother. 65:2428-2435. http://dx.doi.org/10.1093/jac/dkq317.
21. Han S, Kim J, Yim H, Hur J, Song W, Lee J, Jeon S, Hong T, Woo H, Yim D-S. 2013. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection. Antimicrob. Agents Chemother. 57:1006-1011. http://dx.doi.org/10.1128/AAC.01372-12.
22. Lee J, Han S, Jeon S, Hong T, Song W, Woo H, Yim D-S. 2013. Population pharmacokinetic analysis of colistin in burn patients. Antimicrob. Agents Chemother. 57:2141-2146. http://dx.doi.org/10.1128/AAC.00271-13.
23. De Paepe P, Belpaire FM, Buylaert WA. 2002. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin. Pharmacokinet. 41:1135-1151. http://dx.doi.org/10.2165/00003088- 200241140-00002. (Pubitemid 35398690)
24. Vinks AA, den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. 2003. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob. Agents Chemother. 47:541-547. http://dx.doi.org/10.1128/AAC.47.2. 541-547.2003. (Pubitemid 36158079)
25. Bulitta JB, Kinzig M, Jakob V, Holzgrabe U, Sörgel F, Holford NH. 2010. Nonlinear pharmacokinetics of piperacillin in healthy volunteers - implications for optimal dosage regimens. Br. J. Clin. Pharmacol. 70:682-693. http://dx.doi.org/10.1111/j.1365-2125.2010.03750.x.
26. Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F. 2012. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob. Agents Chemother. 56:5715-5723. http://dx.doi.org/10.1128/AAC.00937-12.
27. Gonzalzles TM, Suseno M, Gaydos JM, Schreckenberger PC, Sincak C, Mehta MS, Peterson LR. 2012. Assessment of susceptibility, pharmacodynamics, and therapeutic response for interpretation of piperacillin-tazobactam in vitro activity in the treatment of Pseudomonas aeruginosa infection. Open J. Med. Microbiol. 2:101. http://dx.doi.org/10.4236/ojmm.2012.23015.
28. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724. http://dx.doi.org/10. 1128/AAC.48.12.4718-4724.2004. (Pubitemid 39577677)
29. Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS. 1992. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin. Pharmacol. Ther. 51:32-41. http://dx.doi.org/10.1038/clpt.1992.5.
30. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob. Agents Chemother. 38: 2351-2356. http://dx.doi.org/10. 1128/AAC.38.10.2351. (Pubitemid 24304229)
31. Okereke C, Dudley MN. 1998. Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. J. Antimicrob. Chemother. 41(suppl D):43-49. http://dx.doi.org/10.1093/jac/41.suppl-4.43. (Pubitemid 28284505)
32. Pfaller M, Barry A, Fuchs P, Gerlach E, Hardy D, McLaughlin J. 1992. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/ tazobactam. Eur. J. Clin. Microbiol. Infect. Dis. 11:728-732. http://dx.doi.org/10.1007/BF01989979.